Low rate of toxicity of combined PRRT and CAPTEM therapy in patients with advanced, non resectable, progressive pancreatic and midgut neuroendocrine tumors (NET)

#3264

Introduction: PRRT with 177Lu-DOTATOC combined with chemotherapy (CAPTEM) is an innovative treatment for progressive, advanced, non-resectable GEP-NETs.

Aim(s): The aim of this study was evaluation of the safety of this approach during and after therapy based on clinical follow-up, et least 18 months.

Materials and methods: Prospective, single arm, open-label, phase 2 study, in patients with histologically proven pancreatic NET (panNET) n=14 and midgut NET n=7 (NCT04194125). Patients received 3-4 cycles of 177Lu-DOTA-TOC at 8-12 weekly intervals and chemotherapy (CAPTEM). Adverse Events (AEs) and safety associated with the combination therapy were assessed throughout the treatment and during further clinical follow-up (at least 12 months). AEs was graded using the NCI-CTCAE v5.0.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kolasińska-Ćwikła A

Authors: Zrajkowska A, Kolasińska-Ćwikła A, Nowicka G, Pałucki J, Nowicki M,

Keywords: PRRT and CAPTEM, neuroendocrine tumor, adverse events,